Alastin Skincare Announces Issuance of Fourth U.S. Patent Incorporating TriHex Technology

INhance Post-Injection Serum with TriHex Technology is designed to alleviate bruising caused by cosmetic procedures. Photo Credit: Alastin Skincare

Alastin Skincare announced that the U.S. Patent and Trademark Office has issued a fourth U.S. Patent, No. 10,688,147, incorporating Alastin's platform TriHex Technology. The patent is directed to a topical composition for alleviating bruising caused by a cosmetic procedure—INhance Post-Injection Serum with TriHex Technology. "We are immensely proud of the scientific investment we have made in validating TriHex Technology performance in our product formulations which is confirmed by its numerous patents," says Alan Widgerow, M.D., FACS, and chief medical officer at Alastinn. "INhance Post-Injection Serum combines the anti-aging benefits of patented TriHex Technology and our new ChromaFADE Technology to deliver state-of-the-art post-procedure recovery and skin-enhancing benefits."

RELATED STORIES

What's New in Med Spa Products

4 Out Of 5 People Won't Visit Med Spas Without Safety Standards

Venus Concept Announces FDA 510(k) Clearance for Venus Viva M

Read more on

Suggested Articles

Proper sanitation helps protect against COVID-19.

According to dermatologist Ronald Moy, UV rays can cause damage both indoors and out.

National CBD Day supports cbdMD’s mission to educate consumers on the overarching uses of cannabidiol.